Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health — Canaccord Genuity U.S. Cannabis Symposium 2019
22 slides from Vireo Growth's conference presentation, Oct 3, 2019
Slide 1: Canaccord U.S. Cannabis Symposium
Canaccord U.S. Cannabis Symposium October 3, 2019 CNSX: VREO OTCQX: VREOF
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-lo
Slide 3: Our Mission
Our Mission “We are building the cannabis company of the future by bringing the best of science, medicine and engineering to the cannabis industry.” - Kyle Kingsley, M.D. Founder & CEO Our Mission || 3
Slide 4: Vireo By The Numbers
Vireo By The Numbers 400+ 11 7 Employees States (1) Research Partnerships 18.5M 80M 13 FY18 Revenue Addressable Patents-Pending Market Population 11 32 2 Manufacturing Dispensary Hemp Licenses Licenses Licenses (1) Including Puerto Rico. Vireo By The Numbers || 4
Slide 5: Corporate Timeline
Corporate Timeline June 2019 December 2014 September 2015 May 2017 August 2017 July 2018 December 2018 March 2019 Completed Awarded 1 of 2 Midwest Hemp Launched first Participation in Awarded cultivation, Awarded 3 Retail Executed RTO acquisition of vertically integrated Research harvests cannabis a
Slide 6: Vireo's Footprint
Vireo’s Footprint MN MA NY RI PA NV OH CA MD AZ NM Current Footprint Subject to pending transactions Hemp assets Puerto Rico Vireo’s Footprint|| 6
Slide 7: State-by-State Snapshot of Operations
State-by-State Snapshot of Operations: (1) Minnesota New York Pennsylvania Maryland Ohio Rhode Island Arizona Puerto Rico Nevada Massachusetts New Mexico California Population 5.6 19.9 12.8 6.0 11.7 1.1 7.0 3.7 3.1 6.9 2.1 39.8 (MM) Status Current Current Current Current Current Current Current Curr
Slide 8: Leadership Team
Leadership Team Kyle Kingsley, M.D. – Chief Executive Officer Amber Shimpa – Chief Financial Officer Dr. Kingsley is a board-certified emergency medicine physician, Amber has served as the Chief Financial Officer of Vireo entrepreneur, and inventor. Dr. Kingsley has a strong track Health since incep
Slide 9: Vireo Strategy
Vireo Strategy Opportunistic Best-in-Class Real Intellectual Growth Customer Experience Property Organic Growth Through Highly Professional Industrial Scale Process Merit-Based License Wins Retail Apparatus and Equipment Cost-Effective M&A Home Delivery Novel Proprietary Activity Cannabis Formulatio
Slide 10: Best-in-Class Customer Experience: Retail Dispensaries
Best-in-Class Customer Experience: Best-in-Class Customer Experience: Retail Dispensaries Retail Dispensaries Green Goods™ Dispensary Concept Launching in Pennsylvania Slide content reflects build-out of Bethlehem, PA location Best-in-Class FY18 Results Customer Conference Experience Call || || 10
Slide 11: Best-in-Class Customer Experience: Home Delivery & In-Store Pick-Up
Best-in-Class Customer Experience: Home Delivery & In-Store Pick-Up Best-in-Class Customer Experience || 11
Slide 12: Best in Class Customer Experience: Brands
Best In Class Customer Experience: Brands Pharmaceutical-grade High Potency Products for High-Quality, Innovative Balanced, Comfortable, Products Geared Toward a Sophisticated Consumer Products for a Curious, Reliable Products for Patients Socially-Conscious Consumer Everyday Wellness Vireo Brands |
Slide 13: Real Intellectual Property: Research Partners
Real Intellectual Property: Research Partners Exclusive agreement to study the Randomized trial of medical Study to evaluate cannabis use IRB-approved research study to use of Captisol in the development cannabis in patients with newly among older adults – how they examine older adults’ use of and c
Slide 14: Real Intellectual Property: Current Portfolio
Real Intellectual Property: Current Portfolio Short Term Monetization Long-Term Applications Cannabis Moist Snuff Composition Harm Reduction Additive for Tobacco Products Multi-Channel Vaporizer Method for Treating Non-Cannabinoid Negative Control Antidepressant Withdrawal Formulations (Placebo) Syn
Slide 15: Real Intellectual Property: Hemp
Real Intellectual Property: Hemp Vireo is focused on the multi-billion dollar hemp market opportunity by developing combine-friendly, high- cannabinoid cannabis cultivars along with innovative consumer products. Midwest Hemp 1776 Hemp Research - Minnesota – New York Licensed to Cultivate and License
Slide 16: Fiscal Year 2019 Development Plans
Fiscal Year 2019 Development Plans During fiscal year 2019, Vireo expects to: • Launch Green Goods™ dispensaries in Pennsylvania and expand its retail footprint in New Mexico • Increase cultivation and processing capacity in Arizona, Minnesota, New Mexico and New York • Begin building new facilities
Slide 17: Board of Directors
Board of Directors Kyle Kingsley, M.D. – Chairman, Chief Executive Officer Amber Shimpa – Chief Financial Officer Dr. Kingsley is a board-certified emergency medicine physician, Amber has served as the Chief Financial Officer of Vireo entrepreneur, and inventor. Dr. Kingsley has a strong track Healt
Slide 18: Slide 18
Slide 19: Key Second Quarter 2019 Financial Metrics
Key Second Quarter 2019 Financial Metrics Three Months Ended Six Months Ended June 30, June 30, $ in millions 2019 2018 Variance 2019 2018 Variance Revenue $7.2 $4.2 $3.0 $13.0 $7.9 $5.1 Gross Profit Before Fair Value Adjustments $2.5 $2.4 $0.1 $5.2 $4.2 $1.0 % Margin 35.3% 56.6% -2,134 bps 40.4% 53
Slide 20: Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) || 20
Slide 21: Consolidated Statements of Financial Position
Consolidated Statements of Financial Position || 21
Slide 22: Reconciliation of IFRS to Non-IFRS Financial Measures
Reconciliation of IFRS to Non-IFRS Financial Measures Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Net income (loss) $ (1,872,457) $ 120,080 $ (5,319,214) $ (1,909,622) Listing expense - - 3,464,611 - Acquisition related costs 772,110 - 772,110 - Write down of inventory
Vireo Health — Canaccord Genuity U.S. Cannabis Symposium 2019 on 6ix